nodes	percent_of_prediction	percent_of_DWPC	metapath
Naltrexone—UGT1A1—Rifampicin—leprosy	0.719	0.834	CbGbCtD
Naltrexone—ABCB1—Rifampicin—leprosy	0.143	0.165	CbGbCtD
Naltrexone—Suicide attempt—Dapsone—leprosy	0.00575	0.0415	CcSEcCtD
Naltrexone—Sexual dysfunction—Thalidomide—leprosy	0.00298	0.0215	CcSEcCtD
Naltrexone—Suicide attempt—Thalidomide—leprosy	0.00294	0.0213	CcSEcCtD
Naltrexone—Platelet count decreased—Thalidomide—leprosy	0.00281	0.0203	CcSEcCtD
Naltrexone—Deep vein thrombosis—Thalidomide—leprosy	0.00274	0.0198	CcSEcCtD
Naltrexone—Toothache—Thalidomide—leprosy	0.00274	0.0198	CcSEcCtD
Naltrexone—Seborrhoeic dermatitis—Thalidomide—leprosy	0.00245	0.0177	CcSEcCtD
Naltrexone—Psychotic disorder—Dapsone—leprosy	0.00231	0.0167	CcSEcCtD
Naltrexone—Nasopharyngitis—Dapsone—leprosy	0.00212	0.0153	CcSEcCtD
Naltrexone—Influenza—Dapsone—leprosy	0.00205	0.0148	CcSEcCtD
Naltrexone—Musculoskeletal stiffness—Thalidomide—leprosy	0.00186	0.0134	CcSEcCtD
Naltrexone—Cellulitis—Thalidomide—leprosy	0.00184	0.0133	CcSEcCtD
Naltrexone—Thinking abnormal—Thalidomide—leprosy	0.00182	0.0132	CcSEcCtD
Naltrexone—Hypercholesterolaemia—Thalidomide—leprosy	0.00177	0.0128	CcSEcCtD
Naltrexone—Sinusitis—Dapsone—leprosy	0.00171	0.0124	CcSEcCtD
Naltrexone—Pulmonary embolism—Thalidomide—leprosy	0.00167	0.0121	CcSEcCtD
Naltrexone—Pharyngitis—Dapsone—leprosy	0.00163	0.0117	CcSEcCtD
Naltrexone—Colitis—Thalidomide—leprosy	0.0016	0.0116	CcSEcCtD
Naltrexone—Tinnitus—Dapsone—leprosy	0.00153	0.011	CcSEcCtD
Naltrexone—Hyperkinesia—Thalidomide—leprosy	0.00146	0.0105	CcSEcCtD
Naltrexone—Mental disability—Thalidomide—leprosy	0.00145	0.0105	CcSEcCtD
Naltrexone—Euphoric mood—Thalidomide—leprosy	0.00143	0.0104	CcSEcCtD
Naltrexone—Lymphadenopathy—Thalidomide—leprosy	0.00142	0.0103	CcSEcCtD
Naltrexone—Gastroenteritis—Thalidomide—leprosy	0.00137	0.00988	CcSEcCtD
Naltrexone—Vision blurred—Dapsone—leprosy	0.00134	0.00971	CcSEcCtD
Naltrexone—Cardiac failure congestive—Thalidomide—leprosy	0.00134	0.00966	CcSEcCtD
Naltrexone—Libido decreased—Thalidomide—leprosy	0.00131	0.00944	CcSEcCtD
Naltrexone—Increased appetite—Thalidomide—leprosy	0.00129	0.00932	CcSEcCtD
Naltrexone—Atrial fibrillation—Thalidomide—leprosy	0.00128	0.00924	CcSEcCtD
Naltrexone—Purpura—Thalidomide—leprosy	0.00126	0.00908	CcSEcCtD
Naltrexone—Arthritis—Thalidomide—leprosy	0.00125	0.00901	CcSEcCtD
Naltrexone—Cough—Dapsone—leprosy	0.00124	0.00899	CcSEcCtD
Naltrexone—Lethargy—Thalidomide—leprosy	0.00124	0.00894	CcSEcCtD
Naltrexone—Gastrointestinal haemorrhage—Thalidomide—leprosy	0.00121	0.00876	CcSEcCtD
Naltrexone—Pain in extremity—Thalidomide—leprosy	0.00121	0.00876	CcSEcCtD
Naltrexone—Disturbance in sexual arousal—Thalidomide—leprosy	0.0012	0.00869	CcSEcCtD
Naltrexone—Migraine—Thalidomide—leprosy	0.00119	0.00862	CcSEcCtD
Naltrexone—Psychotic disorder—Thalidomide—leprosy	0.00118	0.00855	CcSEcCtD
Naltrexone—Face oedema—Thalidomide—leprosy	0.00117	0.00845	CcSEcCtD
Naltrexone—Tachycardia—Dapsone—leprosy	0.00114	0.0082	CcSEcCtD
Naltrexone—Dehydration—Thalidomide—leprosy	0.00113	0.00814	CcSEcCtD
Naltrexone—Aspartate aminotransferase increased—Thalidomide—leprosy	0.00109	0.00788	CcSEcCtD
Naltrexone—Cramp muscle—Thalidomide—leprosy	0.00109	0.00788	CcSEcCtD
Naltrexone—Alanine aminotransferase increased—Thalidomide—leprosy	0.00107	0.00772	CcSEcCtD
Naltrexone—Insomnia—Dapsone—leprosy	0.00105	0.0076	CcSEcCtD
Naltrexone—Influenza—Thalidomide—leprosy	0.00105	0.00757	CcSEcCtD
Naltrexone—Angina pectoris—Thalidomide—leprosy	0.00102	0.00737	CcSEcCtD
Naltrexone—Bronchitis—Thalidomide—leprosy	0.00101	0.00728	CcSEcCtD
Naltrexone—Upper respiratory tract infection—Thalidomide—leprosy	0.000973	0.00703	CcSEcCtD
Naltrexone—Weight increased—Thalidomide—leprosy	0.000953	0.00689	CcSEcCtD
Naltrexone—Gastrointestinal pain—Dapsone—leprosy	0.000951	0.00687	CcSEcCtD
Naltrexone—Weight decreased—Thalidomide—leprosy	0.000948	0.00685	CcSEcCtD
Naltrexone—Pneumonia—Thalidomide—leprosy	0.000939	0.00679	CcSEcCtD
Naltrexone—Infestation NOS—Thalidomide—leprosy	0.000934	0.00675	CcSEcCtD
Naltrexone—Infestation—Thalidomide—leprosy	0.000934	0.00675	CcSEcCtD
Naltrexone—Depression—Thalidomide—leprosy	0.000931	0.00673	CcSEcCtD
Naltrexone—Acute coronary syndrome—Thalidomide—leprosy	0.000921	0.00665	CcSEcCtD
Naltrexone—Abdominal pain—Dapsone—leprosy	0.00092	0.00665	CcSEcCtD
Naltrexone—Body temperature increased—Dapsone—leprosy	0.00092	0.00665	CcSEcCtD
Naltrexone—Myocardial infarction—Thalidomide—leprosy	0.000915	0.00661	CcSEcCtD
Naltrexone—Conjunctivitis—Thalidomide—leprosy	0.000908	0.00656	CcSEcCtD
Naltrexone—Epistaxis—Thalidomide—leprosy	0.000881	0.00636	CcSEcCtD
Naltrexone—Sinusitis—Thalidomide—leprosy	0.000876	0.00633	CcSEcCtD
Naltrexone—Hepatitis—Thalidomide—leprosy	0.000838	0.00606	CcSEcCtD
Naltrexone—Pharyngitis—Thalidomide—leprosy	0.000832	0.00601	CcSEcCtD
Naltrexone—Eye disorder—Thalidomide—leprosy	0.000783	0.00566	CcSEcCtD
Naltrexone—Tinnitus—Thalidomide—leprosy	0.000782	0.00565	CcSEcCtD
Naltrexone—Cardiac disorder—Thalidomide—leprosy	0.000778	0.00562	CcSEcCtD
Naltrexone—Angiopathy—Thalidomide—leprosy	0.000761	0.0055	CcSEcCtD
Naltrexone—Immune system disorder—Thalidomide—leprosy	0.000757	0.00547	CcSEcCtD
Naltrexone—Mediastinal disorder—Thalidomide—leprosy	0.000756	0.00546	CcSEcCtD
Naltrexone—Chills—Thalidomide—leprosy	0.000752	0.00544	CcSEcCtD
Naltrexone—Alopecia—Thalidomide—leprosy	0.000741	0.00535	CcSEcCtD
Naltrexone—Vomiting—Dapsone—leprosy	0.00074	0.00535	CcSEcCtD
Naltrexone—Mental disorder—Thalidomide—leprosy	0.000735	0.00531	CcSEcCtD
Naltrexone—Malnutrition—Thalidomide—leprosy	0.00073	0.00527	CcSEcCtD
Naltrexone—Headache—Dapsone—leprosy	0.000729	0.00527	CcSEcCtD
Naltrexone—Flatulence—Thalidomide—leprosy	0.000719	0.0052	CcSEcCtD
Naltrexone—Tension—Thalidomide—leprosy	0.000716	0.00517	CcSEcCtD
Naltrexone—Dysgeusia—Thalidomide—leprosy	0.000715	0.00516	CcSEcCtD
Naltrexone—Nervousness—Thalidomide—leprosy	0.000709	0.00512	CcSEcCtD
Naltrexone—Back pain—Thalidomide—leprosy	0.000706	0.0051	CcSEcCtD
Naltrexone—Muscle spasms—Thalidomide—leprosy	0.000702	0.00507	CcSEcCtD
Naltrexone—Nausea—Dapsone—leprosy	0.000691	0.00499	CcSEcCtD
Naltrexone—Vision blurred—Thalidomide—leprosy	0.000688	0.00497	CcSEcCtD
Naltrexone—Tremor—Thalidomide—leprosy	0.000684	0.00494	CcSEcCtD
Naltrexone—Ill-defined disorder—Thalidomide—leprosy	0.000677	0.00489	CcSEcCtD
Naltrexone—Agitation—Thalidomide—leprosy	0.000671	0.00485	CcSEcCtD
Naltrexone—Angioedema—Thalidomide—leprosy	0.000667	0.00482	CcSEcCtD
Naltrexone—Malaise—Thalidomide—leprosy	0.000658	0.00476	CcSEcCtD
Naltrexone—Syncope—Thalidomide—leprosy	0.000654	0.00473	CcSEcCtD
Naltrexone—Palpitations—Thalidomide—leprosy	0.000645	0.00466	CcSEcCtD
Naltrexone—Loss of consciousness—Thalidomide—leprosy	0.000641	0.00463	CcSEcCtD
Naltrexone—Cough—Thalidomide—leprosy	0.000637	0.0046	CcSEcCtD
Naltrexone—Convulsion—Thalidomide—leprosy	0.000632	0.00457	CcSEcCtD
Naltrexone—Hypertension—Thalidomide—leprosy	0.00063	0.00455	CcSEcCtD
Naltrexone—Chest pain—Thalidomide—leprosy	0.000621	0.00449	CcSEcCtD
Naltrexone—Myalgia—Thalidomide—leprosy	0.000621	0.00449	CcSEcCtD
Naltrexone—Arthralgia—Thalidomide—leprosy	0.000621	0.00449	CcSEcCtD
Naltrexone—Anxiety—Thalidomide—leprosy	0.000619	0.00447	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Thalidomide—leprosy	0.000617	0.00446	CcSEcCtD
Naltrexone—Discomfort—Thalidomide—leprosy	0.000614	0.00444	CcSEcCtD
Naltrexone—Dry mouth—Thalidomide—leprosy	0.000608	0.00439	CcSEcCtD
Naltrexone—Confusional state—Thalidomide—leprosy	0.000601	0.00434	CcSEcCtD
Naltrexone—Oedema—Thalidomide—leprosy	0.000596	0.0043	CcSEcCtD
Naltrexone—Infection—Thalidomide—leprosy	0.000592	0.00428	CcSEcCtD
Naltrexone—Shock—Thalidomide—leprosy	0.000586	0.00423	CcSEcCtD
Naltrexone—Nervous system disorder—Thalidomide—leprosy	0.000584	0.00422	CcSEcCtD
Naltrexone—Tachycardia—Thalidomide—leprosy	0.000581	0.0042	CcSEcCtD
Naltrexone—Skin disorder—Thalidomide—leprosy	0.000579	0.00418	CcSEcCtD
Naltrexone—Hyperhidrosis—Thalidomide—leprosy	0.000576	0.00416	CcSEcCtD
Naltrexone—Anorexia—Thalidomide—leprosy	0.000568	0.0041	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Thalidomide—leprosy	0.000543	0.00392	CcSEcCtD
Naltrexone—Insomnia—Thalidomide—leprosy	0.000539	0.00389	CcSEcCtD
Naltrexone—Paraesthesia—Thalidomide—leprosy	0.000535	0.00386	CcSEcCtD
Naltrexone—Dyspnoea—Thalidomide—leprosy	0.000531	0.00384	CcSEcCtD
Naltrexone—Somnolence—Thalidomide—leprosy	0.00053	0.00383	CcSEcCtD
Naltrexone—Decreased appetite—Thalidomide—leprosy	0.000518	0.00374	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Thalidomide—leprosy	0.000514	0.00372	CcSEcCtD
Naltrexone—Fatigue—Thalidomide—leprosy	0.000514	0.00371	CcSEcCtD
Naltrexone—Pain—Thalidomide—leprosy	0.000509	0.00368	CcSEcCtD
Naltrexone—Constipation—Thalidomide—leprosy	0.000509	0.00368	CcSEcCtD
Naltrexone—Feeling abnormal—Thalidomide—leprosy	0.000491	0.00355	CcSEcCtD
Naltrexone—Gastrointestinal pain—Thalidomide—leprosy	0.000487	0.00352	CcSEcCtD
Naltrexone—Urticaria—Thalidomide—leprosy	0.000473	0.00342	CcSEcCtD
Naltrexone—Abdominal pain—Thalidomide—leprosy	0.000471	0.0034	CcSEcCtD
Naltrexone—Body temperature increased—Thalidomide—leprosy	0.000471	0.0034	CcSEcCtD
Naltrexone—Hypersensitivity—Thalidomide—leprosy	0.000439	0.00317	CcSEcCtD
Naltrexone—Asthenia—Thalidomide—leprosy	0.000427	0.00309	CcSEcCtD
Naltrexone—Pruritus—Thalidomide—leprosy	0.000421	0.00304	CcSEcCtD
Naltrexone—Diarrhoea—Thalidomide—leprosy	0.000408	0.00294	CcSEcCtD
Naltrexone—Dizziness—Thalidomide—leprosy	0.000394	0.00285	CcSEcCtD
Naltrexone—Vomiting—Thalidomide—leprosy	0.000379	0.00274	CcSEcCtD
Naltrexone—Rash—Thalidomide—leprosy	0.000376	0.00271	CcSEcCtD
Naltrexone—Dermatitis—Thalidomide—leprosy	0.000375	0.00271	CcSEcCtD
Naltrexone—Headache—Thalidomide—leprosy	0.000373	0.0027	CcSEcCtD
Naltrexone—Nausea—Thalidomide—leprosy	0.000354	0.00256	CcSEcCtD
